Revvity (NYSE:RVTY) Hits New 12-Month High – Here’s Why

Revvity Inc. (NYSE:RVTY)’s share price reached a new 52-week high during mid-day trading on Friday. The company traded as high as $152.26 and last traded at $150.9550, with a volume of 2539808 shares changing hands. The stock had previously closed at $142.11.

Trending Headlines about Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity launched a CE-IVDR-certified automated screening kit in Europe to detect type 1 diabetes risk in children. The product expands the company’s GSP platform beyond newborn screening and could broaden its diagnostics revenue opportunity. RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection
• Positive Sentiment: The diabetes-test launch has attracted favorable market attention and helped push Revvity shares toward a new one-year high, reinforcing momentum in the stock. Revvity Hits New 1-Year High
• Neutral Sentiment: Revvity recently exceeded quarterly EPS and revenue expectations, reporting $1.41 EPS versus a $1.21 consensus estimate and $729.7 million in revenue versus $703.0 million expected. However, revenue declined 1.3% year over year, and fiscal 2026 EPS guidance remains $5.30-$5.40.
• Neutral Sentiment: Analysts maintain a consensus “Hold” rating, with a reported average price target of $116.57, below the current trading range. UBS and RBC also initiated coverage with neutral or sector-perform ratings.
• Negative Sentiment: Insider Maxwell Krakowiak sold 1,631 shares worth approximately $235,700, reducing his direct ownership by nearly 10%. The sale is relatively small but may add a modest cautionary signal after the recent rally. Revvity Insider Sells 1,631 Shares

Analysts Set New Price Targets

A number of equities analysts have weighed in on RVTY shares. Wolfe Research assumed coverage on shares of Revvity in a research note on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Sanford C. Bernstein began coverage on shares of Revvity in a report on Friday, June 26th. They issued a “market perform” rating and a $115.00 price target on the stock. Zacks Research raised shares of Revvity from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Wall Street Zen downgraded Revvity from a “buy” rating to a “hold” rating in a report on Sunday, August 16th. Finally, UBS Group assumed coverage on Revvity in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $140.00 target price on the stock. Four equities research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $116.57.

Revvity Price Performance

The company’s fifty day moving average is $124.13 and its 200 day moving average is $106.49. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36. The stock has a market cap of $16.83 billion, a PE ratio of 71.83, a price-to-earnings-growth ratio of 2.75 and a beta of 1.09.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The firm had revenue of $729.69 million for the quarter, compared to analysts’ expectations of $702.96 million. During the same period in the previous year, the company posted $1.18 earnings per share. Revvity’s revenue was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts anticipate that Revvity Inc. will post 5.36 earnings per share for the current fiscal year.

Revvity Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity’s dividend payout ratio is currently 13.33%.

Insider Activity

In other news, insider Tajinder S. Vohra sold 7,330 shares of the company’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total value of $1,032,650.40. Following the completion of the sale, the insider owned 6,635 shares of the company’s stock, valued at $934,738.80. This represents a 52.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Maxwell Krakowiak sold 1,631 shares of the stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $144.53, for a total value of $235,728.43. Following the completion of the sale, the insider owned 14,781 shares of the company’s stock, valued at approximately $2,136,297.93. This trade represents a 9.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 9,046 shares of company stock worth $1,277,685 over the last three months. 0.85% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Revvity

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Jupiter Topco LLC acquired a new stake in Revvity in the second quarter valued at approximately $961,017,000. BlackRock Inc. purchased a new stake in shares of Revvity during the second quarter valued at approximately $852,070,000. Wellington Management Group LLP lifted its position in shares of Revvity by 10,653.8% during the second quarter. Wellington Management Group LLP now owns 865,575 shares of the company’s stock worth $96,304,000 after purchasing an additional 857,526 shares in the last quarter. Primecap Management Co. CA acquired a new position in shares of Revvity during the second quarter worth $94,921,000. Finally, Norges Bank purchased a new position in shares of Revvity in the fourth quarter valued at $80,382,000. 86.65% of the stock is owned by institutional investors and hedge funds.

Revvity Company Profile

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer’s Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.